First-line therapy in atypical hemolytic uremic syndrome: consideration on infants with a poor prognosis

BACKGROUND: Atypical hemolytic uremic syndrome (aHUS) is a rare and heterogeneous disorder. The first line treatment of aHUS is plasma therapy, but in the past few years, the recommendations have changed greatly with the advent of eculizumab, a humanized monoclonal anti C5-antibody. Although recent...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ital J Pediatr
Main Authors: Szarvas, Nóra, Szilágyi, Ágnes, Tasic, Velibor, Nushi-Stavileci, Valbona, Sofijanova, Aspazija, Gucev, Zoran, Szabó, Miklós, Szabó, Attila, Szeifert, Lilla, Reusz, György, Rusai, Krisztina, Arbeiter, Klaus, Müller, Thomas, Prohászka, Zoltán
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2014
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4295478/
https://ncbi.nlm.nih.gov/pubmed/25496981
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13052-014-0101-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados